CNB is supported by the Bingham Chair in Gastroenterology. Dr. Bernstein has served on advisory boards for AbbVie Canada, Amgen Canada, Bristol Myers Squibb Canada, Celltrion, Eli Lilly Canada, Ferring Canada, Fresenius-Kabi Canada, Janssen Canada, Pendopharm Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; Educational grants from AbbVie Canada, Boston Scientific, Bristol Myers Squibb Canada, Eli Lilly, Ferring Canada, Pfizer Canada, Takeda Canada, Janssen Canada, Organon Canada, Eli Lilly Canada, and Amgen Canada. Speaker's panel for AbbVie Canada, Fresenius-Kabi Canada, Janssen Canada, Pfizer Canada, and Takeda Canada. Received research funding from AbbVie Canada, Amgen Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada. CBGF has served on advisory boards for Johnson & Johnson; has participated in speaker panels and educational activities for Johnson & Johnson, Pfizer, and Takeda; has received educational grants from AbbVie, Johnson & Johnson, Nestlé, Pfizer, and Takeda; has received travel support from AbbVie, Johnson & Johnson, Pfizer, Takeda, Nestlé, and ABCD (Associação Brasileira de Colite Ulcerativa e Doença de Crohn); and has been involved in the development of educational materials for Johnson & Johnson and Takeda. CBGF also reports scientific and professional involvement with GEDIIB (Organização Brasileira de Doença de Crohn e Colite) as a member of the Surgical Committee of GEDIIB (unpaid, 2025–2026). CWSJ reports speaker panels for AbbVie, Johnson & Johnson, Takeda, and FQM, and educational grants from Johnson & Johnson. CRFC has a personal research scholarship funded by the Conselho Nacional de Pesquisa de Desenvolvimento Científico e Tecnológico (CNPq) (grant 312279/2018-3). MRFJ reports no conflicts of interest.
PubMed
